Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy (Q35131227)

6 August 2017

1 reference

title

Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy (English)

1 reference

6 August 2017

0 references

1 reference

Jooss K

1

1 reference

6 August 2017

Chirmule N

series ordinal

2

1 reference

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

10

1 reference

6 August 2017

11

1 reference

6 August 2017

955-963

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302037

6 August 2017

0 references

cites work

Gene therapy: trials and tribulations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Danger signals: SOS to the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Toll-like receptors: critical proteins linking innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

New perspectives of CD28-B7-mediated T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Immune responses to adenovirus and adeno-associated virus in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Replication-defective vector based on a chimpanzee adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Persistence in muscle of an adenoviral vector that lacks all viral genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Adenoviral vector-mediated gene transfer for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Adeno-associated virus vectors for gene therapy: more pros than cons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Adeno-associated virus site-specifically integrates into a muscle-specific DNA region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Building a better vector: the manipulation of AAV virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Gene transfer by adeno-associated virus vectors into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Recombinant adeno-associated virus for muscle directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Kinetics of recombinant adeno-associated virus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Toxicity of a first-generation adenoviral vector in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Induction of tolerance to human factor VIII in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Additional transduction events after subretinal readministration of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

Introduction: the role of innate immunity in the adaptive immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

7 January 2021

Worldwide epidemiology of human adenovirus infections

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

7 January 2021

Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

7 January 2021

Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

7 January 2021

Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

7 January 2021

An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

7 January 2021

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302037

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302037

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference